StockMarketWire.com - Biotechnology company PureTech Health said affiliate Vedanta Biosciences had initiated a clinical study regarding an immuno-oncology candidate in patients with types of advanced or metastatic cancer.
The open-label, non-randomised study would evaluate the safety, tolerability and clinical activity of the treatment, called VE800.
The parameters would be measured in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo.
Vedanta would target enrolment of over 100 patients in the US diagnosed with advanced or metastatic melanoma, gastric/gastroesophageal junction adenocarcinoma or microsatellite-stable colorectal cancer.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.